Role of Transcranial Doppler and Magnetic Resonance Angiography for Future Management of Sickle Cell Anemia CNS.

Launched by EMAN ABDUL-HAI · Jul 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how two specific tests, Transcranial Doppler (TCD) and Magnetic Resonance Angiography (MRA), can help manage sickle cell anemia in children. The goal is to find out if these tests can detect brain changes that might not cause any symptoms but could lead to serious conditions like strokes. By identifying abnormalities in blood flow early on, the researchers hope to prevent strokes in children with sickle cell disease (SCD) by providing treatments like blood transfusions.

To participate in this study, children aged 2 to 18 years with a specific type of sickle cell anemia (Hb SS) may be eligible, assuming they can attend follow-up visits for at least two years. Parents will need to give their consent, and the child will need to agree to participate as well. The trial is not yet recruiting participants, but it aims to help improve future care for children with sickle cell anemia by closely monitoring their brain health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) age, from 24 months to 18 years; (2) hemoglobinopathy diagnosis of Hb SS; (3) the desire and ability to be screened as evidenced by signed parental informed consent and child's assent; (4) the availability for follow-up for at least 2 years.
• Exclusion Criteria:
• • - 1.Other sickle cell syndromes were excluded because they had a lower or uncertain risk of stroke.
• • 2.A child was excluded from TCD screening for any of the following: an indication for chronic blood transfusion or a contraindication to chronic transfusion, participation in any study involving treatments which might confound the interpretation of the results of the proposed work